Business
Aditxt Announces Closing of $4.25 Million Public Offering
RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune
About this update from Aditxt, Inc.
[{"type":"text","content":" RICHMOND, Va.--(BUSINESS WIRE)--\nAditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.\n\nAditxt plans to use a portion of the net of underwriting discounts proceeds of approximately $3.91 million from this offering to fund certain obligations under its previously announced Transaction Agreement with AiPharma Global Holdings entered into on October 4, 2021.\n\nRevere Securities, LLC acted as sole book-running manager for the offering. Sheppard, Mullin, Richter & Hampton LLP acted as counsel to Aditxt and Lucosky Brookman LLP acted as counsel to the underwriter.\n\nThe offering of the common stock described above is being made pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-257645), that was previously filed with the Securities and Exchange Commission (\"SEC\") and declared effective by the SEC on July 13, 2021, and the base prospectus contained therein. The final prospectus supplement and accompanying prospectus have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus relating to the offering of common stock may be obtained by contacting Revere Securities, LLC, 650 Fifth Avenue, 35th Floor, NY, NY 10019, [email protected] or (917) 710-5515.\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.\n\nAbout Aditxt\n\nAditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently...